- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Transcript
Given the benefits that DAPA-HF revealed in preventing the worsening of heart failure in patients without diabetes, what is the potential role of dapagliflozin in primary prevention?
Dapagliflozin has 2 key roles when it comes to thinking about heart failure. The first is we have very strong evidence that dapagliflozin, and the whole SGLT2 inhibitor family, reduce the risk of incident heart failure. So, if you’ve got type 2 diabetes, 1 of the major risks you face is developing heart failure, and dapagliflozin, like other SGLT2 inhibitors, unequivocally reduces that risk substantially. What's new is that we now know that dapagliflozin is also a treatment for established heart failure. So, moving from prevention to treatment, we can treat patients with heart failure both with and without type 2 diabetes.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
